Skip to content
Top Menu
May 16, 2026
  • Home
  • About ScandAsia
  • Advertisement rates
  • Contact us
Scandasia

Nordic News, Business and Life in Asia

  • Home
    • Home
    • What is ScandAsia?
    • Advertisement rates
    • ScandAsia Magazines
    • ScandAsia eNews
    • Thailand Expat Guide
    • Contact us
    • Privacy Policy – Users
  • Business in Asia
    • Business in Asia
    • Agriculture, fishing, forestry
    • Oil and Gas, Mining
    • Construction, infrastructure
    • Transportation, maritime
    • Energy
    • Manufacturing
    • Automotive
    • Food & Beverage
    • Textile
    • IT Telecom
    • Trading & Logistics
    • Banking, Fintech
    • Hospitality
    • Healthcare
    • Retail & Wholesale
    • Services
    • Education
    • Innovation & Technology
    • Entrepreneurship
    • Sustainability
  • ScandAsia News
    • China
    • Hong Kong
    • Thailand
    • Malaysia
    • Singapore
    • Indonesia
    • Philippines
    • Taiwan
    • Vietnam
    • Cambodia
    • Laos
    • Myanmar
    • Denmark
    • Sweden
    • Norway
    • Finland
    • Iceland
  • Living in Asia
    • Basic guides
    • Moving to Asia
    • Working in Asia
    • Studying in Asia
    • Doing things legally
    • Schools News
    • Home and Garden
    • Staying healthy
    • Traveling around
    • History & Heritage
      • ScandAsia magazines archive
  • ScandShop
    • Basket
    • Terms and Conditions
    • Privacy Policy – Shop
    • Data Protection Policy
    • Refund and Returns Policy
  • Opinion

Tag: Ozempic

Business in Asia / China / Denmark

Novo Nordisk says Ozempic copycats in China may be delayed

May 7, 2026 - by Alexander Vittrup - Leave a Comment

Danish pharmaceutical company Novo Nordisk said generic versions of its diabetes drug Ozempic could be delayed in China until 2027 due to regulatory data protection rights. The patent for semaglutide, …

Novo Nordisk says Ozempic copycats in China may be delayed Read More
Business in Asia / China / Denmark

Novo Nordisk tests China-developed drug for obesity and diabetes while competition is growing

March 26, 2026 - by Helene Sadjadi-Munk - Leave a Comment

The Danish pharmaceutical giant Novo Nordisk has reported encouraging results from a new diabetes and weight loss drug developed with a Chinese partner, Fierce Biotech reports. The candidate, known as …

Novo Nordisk tests China-developed drug for obesity and diabetes while competition is growing Read More
Business in Asia / China / Denmark / Healthcare

Novo Nordisk will lose patent protection on Saturday

March 20, 2026 - by Freja Nanna Mogensen - Leave a Comment

Novo Nordisk will lose patent protection for its blockbuster drug Ozempic in several major markets from Saturday. The patent expiry opens the door for other manufacturers to produce cheaper generic …

Novo Nordisk will lose patent protection on Saturday Read More
China / Denmark / General news

Novo Nordisk reports strong profits despite production constraints

November 7, 2024 - by Karoline Rosenkrantz Paasch - Leave a Comment

Novo Nordisk, the Danish pharmaceutical giant renowned for its diabetes and weight-loss medications, including the blockbuster drugs Ozempic and Wegovy, announced impressive third-quarter earnings despite challenges with production constraints. Novo …

Novo Nordisk reports strong profits despite production constraints Read More
Business in Asia / Denmark / Healthcare / Indonesia

Novo Nordisk will help combat diabetes in Indonesia

July 11, 2024 - by Lærke Kobberup - Leave a Comment

The Danish pharmaceutical company Novo Nordisk has signes a deal with a Indonesian state-owned drug company called Bio Farma. Their goal is to produce insulin to fight diabetes within Indonesia. …

Novo Nordisk will help combat diabetes in Indonesia Read More
Business in Asia / China / Denmark

Wegovy approved in China

June 25, 2024 - by Lærke Kobberup - Leave a Comment

The popular weight loss medicin Wegovy by the Danish phamaceutical firm Novo Nordisk has been approved for consumers in China. This has been confirmed by an employee at the company. …

Wegovy approved in China Read More
Business in Asia / China / Denmark / Healthcare

Chinese drugmaker seeks approval of Ozempic-like drug

April 4, 2024 - by Charlotte Nike Albrechtsen - Leave a Comment

A Chinese drugmaker applied for approval on 3 April 2024 to sell their biosimilar Ozempic drug in China. This potentially challenges the expansion plans of Novo Nordisk in China, who …

Chinese drugmaker seeks approval of Ozempic-like drug Read More
Business in Asia / China / Denmark / Healthcare

Approaching patent expiration in China may threaten Novo’s billion-dollar business

September 7, 2023September 20, 2023 - by Miabell Mallikka - Leave a Comment

Novo Nordisk has established itself in the medicine market with patents that earn billions. Mainly due to the obesity drug Wegovy and the diabetes medicine Ozempic. Both consists of an …

Approaching patent expiration in China may threaten Novo’s billion-dollar business Read More
Business in Asia / Denmark / Healthcare

Danish Novo Nordisk surpasses LVMH as Europe’s most valuable company

September 3, 2023September 3, 2023 - by Miabell Mallikka - 1 Comment

Danish pharmaceutical company Novo Nordisk has surpassed LVMH and is now Europe’s most valuable listed company. LVMH, the world’s biggest luxury retailer, is currently suffering due to growing concerns about …

Danish Novo Nordisk surpasses LVMH as Europe’s most valuable company Read More
Business in Asia / China / Denmark / Healthcare

Novo Nordisk’s diet drug may land in China soon

June 6, 2023 - by Miabell Mallikka - Leave a Comment

Danish pharmaceutical titan Novo Nordisk has applied to China’s drug regulator to widen the range of use of its diabetes medicine Ozempic. In the US Ozempic is also used as …

Novo Nordisk’s diet drug may land in China soon Read More

Posts pagination

1 2 Next

ScandAsia Recommends:

Scandasia Newsletter

Scandasia Magazine

ScandAsia May 2026

Thailand Expat Guide 2025

Thailand Expat Guide 2025

Latest 20 News Chronologically

BOI Stockholm concludes first Nordic industrial delegation to Thailand

May 15, 2026May 16, 2026

Malaysian Prime minister criticises Norway over blocked missile delivery

May 15, 2026May 15, 2026

Norwegian HydrogenPro restructures global operations and closes China plant

May 15, 2026

China and Norway push to expand krill fishing in Antarctica

May 15, 2026

Chinese pianist receives new music award in Copenhagen

May 15, 2026

Danish pensioner returns to China’s Great Wall Marathon for the 23rd time

May 15, 2026May 15, 2026

Dead chickens led Sisaket man to attack his Swedish in-law

May 14, 2026

Missing rent led police to Swedish firearm stash

May 14, 2026

Taiwan president pops in on Copenhagen Democracy Summit

May 14, 2026

Hong Kong seeks Finnish healthtech partnerships

May 14, 2026

Norwegian award-winning thriller to screen at European Film Festival in Singapore

May 14, 2026

Swedish firm secures huge U.S. fashion deal: Factory is planned to open in Vietnam

May 14, 2026

Norwegian battery company teams up with Chinese giant BYD on green shipping

May 14, 2026

Sweden joins major Philippine infrastructure push

May 14, 2026May 14, 2026

Nokia wins UK appeal in patent dispute with Taiwan’s Acer and Asus

May 13, 2026

Here’s where to find yarn – and a knitting community – in Bangkok

May 13, 2026

Thailand introduces stricter alcohol rules in public areas

May 13, 2026May 13, 2026

Swedish defence company Saab expands in Thailand

May 13, 2026

Swedish universities seek stronger ties with Hong Kong

May 13, 2026

Thailand approves foreign business changes

May 13, 2026

Address

Scandinavian Publishing Co., Ltd.
211 Soi Prasert-Manukitch 29
Prasert-Manukitch Road
Bangkok 10230 – Thailand
Tel: +6629437166

Editor-in-chief: Gregers Moller
Email: [email protected]

Marketing Director: Finn Balslev
Email: [email protected]

Copyright © 2026 Scandasia.
Web by Webstudiet